More buzz about embryonic stem cell treatments in mice and diabetes proves that *yawn* all the millions of dollars (yours, mine and ours) poured into embryonic stem cell research is not even safe for human clinical trials. This report in the New York Times yesterday has a very misleading headline once you get past the glitz and hype :

Stem cell therapy controls diabetes in mice

“Still, a small number of the mice developed tumors, and some experts said the cells might not be well-characterized enough for use in people. In any event, Novocell said it would be several years before any human tests could begin.”

So, tumors again, not ready for human prime time, could be several years (if ever) . . . a familiar drum beat or clanging bell.

Author Profile

Jennifer Lahl, CBC Founder
Jennifer Lahl, CBC Founder
Jennifer Lahl, MA, BSN, RN, is founder and president of The Center for Bioethics and Culture Network. Lahl couples her 25 years of experience as a pediatric critical care nurse, a hospital administrator, and a senior-level nursing manager with a deep passion to speak for those who have no voice. Lahl’s writings have appeared in various publications including Cambridge University Press, the San Francisco Chronicle, the Dallas Morning News, and the American Journal of Bioethics. As a field expert, she is routinely interviewed on radio and television including ABC, CBS, PBS, and NPR. She is also called upon to speak alongside lawmakers and members of the scientific community, even being invited to speak to members of the European Parliament in Brussels to address issues of egg trafficking; she has three times addressed the United Nations during the Commission on the Status of Women on egg and womb trafficking.